We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+7.75%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.7B
AUM Growth
+$80.1M
(+2.2%)
Cap. Flow
-$54.5M
Cap. Flow
% of AUM
-1.47%
Top 10 Holdings %
Top 10 Hldgs %
34.9%
Holding
147
New
53
Increased
24
Reduced
24
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$134M |
| 2 |
Eli Lilly
LLY
|
+$114M |
| 3 |
HOLX
Hologic
HOLX
|
+$80.8M |
| 4 |
NeoGenomics
NEO
|
+$60.6M |
| 5 |
Biogen
BIIB
|
+$55.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$182M |
| 2 |
Intuitive Surgical
ISRG
|
+$103M |
| 3 |
AbbVie
ABBV
|
+$66.8M |
| 4 |
Medtronic
MDT
|
+$61.4M |
| 5 |
Bausch Health
BHC
|
+$60M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.4% |
| 2 | Technology | 1.61% |
| 3 | Financials | 0.67% |
| 4 | Consumer Discretionary | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HARP
51
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $20.8M | 0.56% |
150,000
+9,200
| +7% | +$1.76M |
|
52
UiPath
PATH
$6.39B
| $20.4M | 0.55% |
+300,000
| New | +$22M |
|
|
GRTS
53
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $19.4M | 0.52% |
2,122,064
| – | – |
|
54
SI-BONE Inc
SIBN
$763M
| $18.1M | 0.49% |
575,000
-2,570
| -0.4% | -$83.1K |
|
55
Zai Lab
ZLAB
$2.29B
| $17.7M | 0.48% |
+100,000
| New | +$16.1M |
|
|
ORTX
56
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $16.6M | 0.45% |
378,180
-53,600
| -12% | -$2.99M |
|
57
Aldeyra Therapeutics
ALDX
$104M
| $16.4M | 0.44% |
1,450,000
-1,102,000
| -43% | -$13.3M |
|
|
PHAS
58
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| $16.1M | 0.43% |
4,315,000
+30,000
| +0.7% | +$99.9K |
|
|
SYNH
59
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $15.7M | 0.42% |
+175,000
| New | +$14.8M |
|
60
Sana Biotechnology
SANA
$871M
| $15.3M | 0.41% |
778,597
+46,276
| +6% | +$1.05M |
|
61
SCYNEXIS
SCYX
$38.9M
| $15.2M | 0.41% |
257,500
+99,529
| +63% | +$6.28M |
|
|
ALPN
62
DELISTED
Alpine Immune Sciences Inc
ALPN
| $13.5M | 0.36% |
1,495,000
-16,000
| -1% | -$174K |
|
|
BLU
63
DELISTED
BELLUS Health Inc.
BLU
| $13.2M | 0.36% |
4,250,000
-2,547,400
| -37% | -$9.73M |
|
64
AC Immune
ACIU
$228M
| $12.6M | 0.34% |
+1,584,000
| New | +$10.9M |
|
65
GH Research
GHRS
$1.92B
| $12.2M | 0.33% |
+560,000
| New | +$11.4M |
|
66
Nautilus Biotechnolgy
NAUT
$217M
| $11.4M | 0.31% |
1,125,000
+625,000
| +125% | +$6.77M |
|
67
Werewolf Therapeutics
HOWL
$17.6M
| $11.3M | 0.31% |
+650,265
| New | +$8.91M |
|
68
Zeta Global
ZETA
$5.39B
| $10.9M | 0.3% |
+1,300,000
| New | +$11M |
|
|
CMAX
69
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $10.5M | 0.29% |
+27,247
| New | +$10.8M |
|
70
Prothena Corp
PRTA
$454M
| $9.36M | 0.25% |
+182,000
| New | +$5.68M |
|
71
Cardiff Oncology
CRDF
$65.5M
| $9.28M | 0.25% |
1,395,000
-1,052,700
| -43% | -$8.93M |
|
72
monday.com
MNDY
$3.38B
| $8.94M | 0.24% |
+40,000
| New | +$8.71M |
|
|
ISEE
73
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.83M | 0.24% |
+1,400,010
| New | +$9.03M |
|
74
Doximity
DOCS
$3.9B
| $8.73M | 0.24% |
+150,000
| New | +$8.42M |
|
75
Arrowhead Research
ARWR
$10.1B
| $8.61M | 0.23% |
+104,000
| New | +$7.74M |
|
Similar funds
NM
PWAM
CM
LJAC
NI
MCM
TS
TW
Avidity Partners Management's Q2 2021 Portfolio in Review
As of Q2 2021, Avidity Partners Management held 147 positions worth $3.7B, up 2.2% from $3.62B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Avidity Partners Management's Q2 2021 filing shows 53 new, 24 increased, 24 reduced and 35 closed positions. Its largest new stake was Eli Lilly: 565,500 shares worth $130M. The largest sale was AstraZeneca, an estimated $182M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Technology and Financials.
- Avidity Partners Management's largest Q2 2021 buy was Eli Lilly: 565,500 shares worth $130M.
- Avidity Partners Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $134M increase.
- Avidity Partners Management's biggest Q2 2021 reduction was AbbVie, cutting an estimated $66.8M.
- Avidity Partners Management fully exited AstraZeneca in Q2 2021, selling an estimated $182M.
- Avidity Partners Management's ten largest holdings make up 35% of its $3.7B portfolio in Q2 2021.
- Avidity Partners Management opened 53 new positions and closed 35 in Q2 2021.
- Avidity Partners Management's portfolio value rose 2.2% quarter-over-quarter to $3.7B.
Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.